Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Analysis of Profitability Ratios
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
The valuation ratios exhibit varied trends over the observed period, spanning from July 2020 to July 2025. Generally, the ratios demonstrate a degree of fluctuation, with periods of increase followed by periods of decline, suggesting sensitivity to market conditions and company performance. A notable trend appears to be a general decrease in most ratios from the highs observed in early 2021 to the lows around late 2022, followed by a moderate recovery and stabilization in more recent quarters.
- Price to Earnings (P/E) Ratio
- The P/E ratio increased significantly from 32.34 in July 2020 to a peak of 55.13 in January 2021. Subsequently, it experienced a considerable decline, reaching 23.38 by April 2022. The ratio then showed some volatility, fluctuating between approximately 24 and 31 through 2023 and into early 2024. More recently, the P/E ratio has stabilized around the 27-29 range, with a slight decrease to 25.62 in October 2024 and a further decline to 23.73 in January 2025, before increasing to 25.37 and 28.35 in the following quarters.
- Price to Operating Profit (P/OP) Ratio
- Similar to the P/E ratio, the P/OP ratio rose from 35.86 in July 2020 to 49.88 in January 2021. It then followed a downward trajectory, reaching a low of 17.99 in October 2022. The ratio exhibited a recovery through 2023 and 2024, stabilizing between 19 and 22. The most recent quarters show a slight increase, peaking at 22.10 in July 2024, before decreasing to 20.31 and 20.83, and then 18.58 in January 2025, followed by increases to 19.31 and 21.74.
- Price to Sales (P/S) Ratio
- The P/S ratio demonstrated a gradual increase from 5.11 in July 2020 to 5.74 in July 2021. It then decreased to 3.42 in October 2022. The ratio has remained relatively stable between 3.30 and 3.89 since then, with fluctuations within this range. The latest values indicate a slight increase from 3.30 in January 2025 to 3.46 in April 2025 and 3.89 in July 2025.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio increased from 2.84 in July 2020 to 3.52 in July 2021, before declining to 2.03 in October 2022. It has since shown a modest recovery, fluctuating between 2.05 and 2.78. The most recent quarters show a trend of increasing values, from 2.30 in January 2025 to 2.47 in April 2025 and 2.78 in July 2025.
Overall, the observed ratios suggest a period of heightened valuation in early 2021, followed by a correction and subsequent stabilization. The recent trends indicate a potential for renewed, albeit moderate, increases in valuation multiples, though further observation is needed to confirm this pattern.
Price to Earnings (P/E)
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Net income attributable to Medtronic (in millions) | ||||||||||||||||||||||||||||||
| Earnings per share (EPS)2 | ||||||||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/E ratio4 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
EPS
= (Net income attributable to MedtronicQ3 2026
+ Net income attributable to MedtronicQ2 2026
+ Net income attributable to MedtronicQ1 2026
+ Net income attributable to MedtronicQ4 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Medtronic PLC Quarterly or Annual Report.
4 Q3 2026 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
The price to earnings (P/E) ratio for the observed period demonstrates considerable fluctuation. Initially, the ratio exhibited a strong upward trend, peaking in early 2021, followed by a period of decline and stabilization, and then renewed volatility. A detailed examination reveals distinct phases in the ratio’s behavior.
- Initial Increase (July 2020 – January 2021)
- The P/E ratio increased significantly from 32.34 in July 2020 to a high of 55.13 in January 2021. This increase occurred alongside a rising share price and a decreasing earnings per share (EPS), indicating growing investor optimism relative to earnings. The most substantial increase occurred between October 2020 and January 2021.
- Decline and Stabilization (February 2021 – July 2022)
- Following the peak, the P/E ratio experienced a notable decline, reaching 22.61 by July 2022. This period coincided with a relatively stable share price and increasing EPS. The decline suggests a correction in valuation as earnings grew to meet investor expectations. The ratio fluctuated within a narrower range during this phase, indicating a period of relative stability.
- Renewed Volatility (August 2022 – October 2024)
- From August 2022, the P/E ratio demonstrated increased volatility. It rose to 26.88 in January 2023, then decreased to 23.73 in January 2025, and subsequently increased to 28.35 in April 2025. This period was characterized by fluctuations in both share price and EPS, resulting in a less predictable P/E ratio. The ratio generally remained between 23 and 31 during this time.
- Recent Trend (November 2024 – July 2025)
- The most recent observations indicate a further increase in the P/E ratio, reaching 26.93 in January 2026. This increase is associated with a rising share price and a relatively stable EPS. The latest values suggest a potential shift towards increased investor confidence or a re-evaluation of future growth prospects.
Overall, the P/E ratio has exhibited a dynamic pattern over the observed period. The initial surge, followed by a correction and subsequent volatility, suggests sensitivity to changes in both earnings and investor sentiment. The recent upward trend warrants further monitoring to determine if it represents a sustained shift in valuation.
Price to Operating Profit (P/OP)
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Operating profit (in millions) | ||||||||||||||||||||||||||||||
| Operating profit per share2 | ||||||||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/OP ratio4 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Operating profit per share
= (Operating profitQ3 2026
+ Operating profitQ2 2026
+ Operating profitQ1 2026
+ Operating profitQ4 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Medtronic PLC Quarterly or Annual Report.
4 Q3 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
The Price to Operating Profit (P/OP) ratio for the observed period demonstrates considerable fluctuation. Initially, the ratio exhibited an increasing trend, followed by a period of decline and subsequent stabilization with renewed variability. A detailed examination reveals distinct phases in the ratio’s behavior.
- Initial Increasing Trend (Jul 31, 2020 – Jan 28, 2022)
- From July 31, 2020, to January 28, 2022, the P/OP ratio generally increased, rising from 35.86 to 25.40. This suggests that the market valuation relative to operating profit was expanding during this timeframe. The most significant increase occurred between July 31, 2020, and January 29, 2021, moving from 35.86 to 49.88. This could indicate growing investor confidence or expectations regarding future profitability.
- Subsequent Decline and Stabilization (Apr 29, 2022 – Oct 27, 2023)
- Following January 28, 2022, the P/OP ratio experienced a notable decline, reaching a low of 17.99 by October 28, 2022. The ratio then stabilized within a relatively narrow range, fluctuating between approximately 18.94 and 21.20 from October 27, 2023, to October 27, 2023. This period suggests a potential correction in market valuation or a shift in investor sentiment.
- Recent Volatility (Jan 26, 2024 – Oct 24, 2025)
- From January 26, 2024, the P/OP ratio has demonstrated increased volatility. It rose to 21.74 in January 2026, before decreasing to 20.60. This recent fluctuation could be attributed to various factors, including changes in market conditions, company-specific news, or broader economic trends. The ratio currently sits at 20.60, indicating a valuation that is within the range observed during the stabilization period but with a renewed sense of movement.
- Overall Trend
- While the P/OP ratio has fluctuated considerably, there isn't a clear, sustained upward or downward trend over the entire period. The ratio appears to be cyclical, with periods of expansion followed by periods of contraction. The most recent data suggests a potential for continued volatility, requiring further monitoring to determine a more definitive long-term trend.
In summary, the P/OP ratio has exhibited dynamic behavior over the analyzed period. The observed patterns suggest that market valuation relative to operating profit is sensitive to various internal and external factors, and requires ongoing assessment.
Price to Sales (P/S)
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Net sales (in millions) | ||||||||||||||||||||||||||||||
| Sales per share2 | ||||||||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/S ratio4 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
Sales per share
= (Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026
+ Net salesQ4 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Medtronic PLC Quarterly or Annual Report.
4 Q3 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
The price-to-sales (P/S) ratio for the observed period demonstrates considerable fluctuation. Initially, the ratio exhibited an increasing trend, followed by a significant decline and subsequent stabilization with moderate variations. A detailed examination reveals distinct phases in the ratio’s behavior.
- Initial Increasing Trend (Jul 31, 2020 – Jul 30, 2021)
- From July 2020 to July 2021, the P/S ratio generally increased, moving from 5.11 to 5.74. This suggests a growing investor confidence in the company’s ability to generate sales relative to its market capitalization during this period. The increase, while present, was not dramatic, indicating a measured response by the market.
- Sharp Decline (Oct 29, 2021 – Apr 29, 2022)
- A substantial decrease in the P/S ratio occurred between October 2021 and April 2022, falling from 4.54 to a low of 3.72. This decline coincided with a decrease in the share price, suggesting potential market concerns regarding future sales performance or broader economic factors impacting valuation. The magnitude of this drop is noteworthy.
- Stabilization and Fluctuation (Jul 29, 2022 – Apr 26, 2024)
- Following the decline, the P/S ratio stabilized within a relatively narrow range, fluctuating between 3.30 and 3.50. This period indicates a period of consolidation, where the market appeared to reassess the company’s valuation based on its sales. The ratio remained relatively consistent, suggesting a balanced view of the company’s prospects.
- Recent Increase (Jul 26, 2024 – Jan 23, 2026)
- From July 2024 to January 2026, the P/S ratio experienced another upward trend, rising from 3.50 to 3.89, and then to 3.50. This recent increase could be attributed to improved investor sentiment, positive sales growth expectations, or a re-evaluation of the company’s long-term potential. The latest value suggests a renewed, though moderate, increase in investor willingness to pay for each dollar of sales.
Overall, the P/S ratio demonstrates a dynamic relationship with market conditions and investor expectations. The observed fluctuations warrant further investigation into the underlying drivers of sales and share price movements to fully understand the valuation trends.
Price to Book Value (P/BV)
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Shareholders’ equity (in millions) | ||||||||||||||||||||||||||||||
| Book value per share (BVPS)2 | ||||||||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/BV ratio4 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2026 Calculation
BVPS = Shareholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Medtronic PLC Quarterly or Annual Report.
4 Q3 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
The price-to-book value (P/BV) ratio for the observed period demonstrates fluctuations, generally trending downwards from mid-2021 before a recent increase. Initial values indicate a relatively stable ratio, followed by a period of decline and subsequent recovery. The analysis below details these observations.
- Initial Period (July 2020 – July 2021)
- The P/BV ratio exhibited an upward trend, increasing from 2.84 to a peak of 3.52. This suggests a growing investor confidence in the company’s value relative to its book value during this timeframe. The share price increased more rapidly than book value per share.
- Decline (October 2021 – January 2023)
- A significant decline in the P/BV ratio occurred, falling from 2.77 to a low of 2.03. This coincided with a decrease in the share price, while book value per share remained relatively stable. This suggests investors were placing a lower valuation on the company’s net asset value.
- Stabilization and Recovery (February 2023 – October 2024)
- Following the decline, the P/BV ratio experienced a period of stabilization, fluctuating between 2.05 and 2.38. The share price showed some recovery, but book value per share remained largely consistent. This indicates a potential bottoming out of investor sentiment.
- Recent Trend (November 2024 – July 2025)
- The most recent observations reveal an upward trend in the P/BV ratio, increasing from 2.30 to 2.78. This is driven by a more substantial increase in the share price compared to the book value per share. This suggests renewed investor optimism and a willingness to pay a higher premium for the company’s net assets.
- Book Value per Share
- Book value per share demonstrated a gradual increase from $37.42 in July 2020 to $39.63 in October 2022, before stabilizing and experiencing a slight decline to $38.15 by July 2025. This indicates a consistent, albeit modest, growth in the company’s net asset value over the period.
- Share Price
- The share price exhibited more volatility than book value per share. It peaked at $134.73 in July 2021, then declined significantly to $79.25 in October 2022. Subsequently, the share price recovered to $105.35 in July 2025, demonstrating a cyclical pattern influenced by market conditions and investor sentiment.
In summary, the P/BV ratio reflects a dynamic relationship between share price and book value per share. The observed fluctuations suggest sensitivity to market conditions and investor perceptions of the company’s value. The recent upward trend warrants further investigation to determine its sustainability.